This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Vidal, H. Articles by Casellas, P. Search for Related Content PubMed PubMed Citation Articles by Vidal, H. Articles by Casellas, P.

Identification and Pharmacological Characterization of SRBP-2

A Novel SR31747A-binding Protein

Immunology-Oncology Department, SanofiSynthelabo, F-34184 Montpellier cedex 04 [H. V., S. G., D. C., P. C., T. C., E. B., P. C.]; Molecular and Functional Genomics Department, SanofiSynthelabo, F-31676 Labège Innopole cedex [G. M., P-H. D., G. L.]; and Departments of Pathology [J. S-L.] and Biostatistics [A. K.], Montpellier Cancer Institute, Montpellier cedex, France

SR31747A is a ligand with potent antiproliferative activity against tumor cells and for which three binding proteins have been identified to date: (a) SRBP-1 (also called 1); (b) HIS; and (c) 2. In this study, we characterized an additional SR31747A binding site, i.e., SRBP-2 (SR31747A-binding protein 2). Using an in silico screening approach, we identified this novel sequence, which exhibits 41% homology with HSI. The 1142-bp cDNA was found to encode a 206 amino acid protein not related to SRBP-1. Northern blot analysis of SRBP-2 mRNA expression revealed a single 1.1-kb transcript that was widely expressed in organs; the liver was particularly enriched, and the brain showed the lowest abundance. A murine homologue that exhibited a similar expression pattern was also characterized. Subcellular localization analysis using specific polyclonal antibodies revealed that SRBP-2 had the same nuclear membrane and endoplasmic reticulum localization as other members of the SR31747A-binding protein family. Considering SRBP-2-binding properties, pharmacological analysis clearly highlighted that SRBP-2 was distinct from 2. Scatchard plot analysis revealed K_d values of 10 and 3 nM for SR31747A and Tamoxifen, respectively. In contrast with HSI, the protein also did not exhibit detectable isomerase activity. When analyzing SRBP-2 expression in human breast cancer biopsies, we obtained evidence that SRBP-2 expression, together with SRBP-1 and HSI, may be of interest as a prognostic marker. These findings demonstrated that SRBP-2 represents an additional molecular target for SR31747A, which could help to understand the immunosuppressive and antiproliferative effects of the molecule.